PT2378876T - Formulações de imiquimod com força de dosagem mais baixa e regimes de dosagem curtos para o tratamento da queratose actínica - Google Patents

Formulações de imiquimod com força de dosagem mais baixa e regimes de dosagem curtos para o tratamento da queratose actínica

Info

Publication number
PT2378876T
PT2378876T PT09837849T PT09837849T PT2378876T PT 2378876 T PT2378876 T PT 2378876T PT 09837849 T PT09837849 T PT 09837849T PT 09837849 T PT09837849 T PT 09837849T PT 2378876 T PT2378876 T PT 2378876T
Authority
PT
Portugal
Prior art keywords
dosing regimens
lower dosage
actinic keratosis
dosage strength
imiquimod formulations
Prior art date
Application number
PT09837849T
Other languages
English (en)
Inventor
T Nordsiek Michael
F Levy Sharon
H Lee James
H Kulp James
S Balaji Kodumudi
Meng Tze-Chiang
J Wu Jason
S Bahm Valyn
Babilon Robert
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2378876(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of PT2378876T publication Critical patent/PT2378876T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
PT09837849T 2008-12-19 2009-12-11 Formulações de imiquimod com força de dosagem mais baixa e regimes de dosagem curtos para o tratamento da queratose actínica PT2378876T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13953608P 2008-12-19 2008-12-19
US14473109P 2009-01-14 2009-01-14
US20514509P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
PT2378876T true PT2378876T (pt) 2019-03-01

Family

ID=42316709

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09837849T PT2378876T (pt) 2008-12-19 2009-12-11 Formulações de imiquimod com força de dosagem mais baixa e regimes de dosagem curtos para o tratamento da queratose actínica

Country Status (27)

Country Link
US (13) US20110021555A1 (pt)
EP (1) EP2378876B1 (pt)
AR (1) AR074802A1 (pt)
AU (1) AU2009335943A1 (pt)
BR (1) BRPI0923164A2 (pt)
CL (1) CL2009002183A1 (pt)
CO (1) CO6400171A2 (pt)
CR (1) CR20110338A (pt)
CY (1) CY1121485T1 (pt)
DK (1) DK2378876T3 (pt)
DO (1) DOP2011000195A (pt)
EA (1) EA201100984A1 (pt)
ES (1) ES2720149T3 (pt)
GE (1) GEP20146198B (pt)
HR (1) HRP20190306T1 (pt)
HU (1) HUE041944T2 (pt)
IL (2) IL213628A (pt)
LT (1) LT2378876T (pt)
MX (2) MX2011001555A (pt)
PA (1) PA8855101A1 (pt)
PE (2) PE20100469A1 (pt)
PL (1) PL2378876T3 (pt)
PT (1) PT2378876T (pt)
RS (1) RS58566B1 (pt)
SI (1) SI2378876T1 (pt)
TW (1) TWI442923B (pt)
WO (1) WO2010080345A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110030089A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Transgenic plants with enhanced growth characteristics
US20110030104A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof
US20110021555A1 (en) * 2008-12-19 2011-01-27 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses
AU2010274097B2 (en) * 2009-07-13 2016-06-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US20110319811A1 (en) * 2010-06-25 2011-12-29 Nordsiek Michael T Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
US9072876B2 (en) 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
WO2013040447A2 (en) * 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
US20140357726A1 (en) * 2011-11-30 2014-12-04 Merz Pharma Gmbh & Co. Kgaa Use of pegylated alcohols for the treatment of actinic keratosis
WO2013162828A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
IL293871A (en) 2013-08-30 2022-08-01 Immunogen Inc Antibodies and assays for the detection of folate receptor 1
US9576445B2 (en) 2013-09-06 2017-02-21 Immersion Corp. Systems and methods for generating haptic effects associated with an envelope in audio signals
US9711014B2 (en) 2013-09-06 2017-07-18 Immersion Corporation Systems and methods for generating haptic effects associated with transitions in audio signals
US9619980B2 (en) 2013-09-06 2017-04-11 Immersion Corporation Systems and methods for generating haptic effects associated with audio signals
MX2016004411A (es) * 2013-10-08 2016-07-05 Immunogen Inc Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).
WO2016040638A2 (en) * 2014-09-10 2016-03-17 Washington University Compositions and methods for treatment of pre-cancerous skin lesions
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
BR112019018687A2 (pt) * 2017-03-10 2020-04-07 Athenex Inc métodos de tratamento e/ou prevenção da ceratose actínica
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT610737A (pt) 1955-11-18 1900-01-01
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE9601528D0 (sv) 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US20030007939A1 (en) * 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
SK287112B6 (sk) 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
WO2002102377A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
AU2004220469B2 (en) * 2001-11-29 2010-07-29 3M Innovative Properties Company Methods of improving skin quality
RU2327460C2 (ru) * 2001-11-29 2008-06-27 3М Инновейтив Пропертиз Компани Фармацевтические составы, содержащие иммуномодулятор
US9668972B2 (en) * 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
CA2518082C (en) * 2003-03-13 2013-02-12 3M Innovative Properties Company Methods for diagnosing skin lesions
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7521459B2 (en) 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
US20090232755A1 (en) * 2003-07-28 2009-09-17 Leslie Baumann Combination therapies for treating photodamaged skin
MXPA06002408A (es) 2003-09-02 2006-06-20 3M Innovative Properties Co Metodos relacionados al tratamiento de condiciones asociadas a la mucosa.
AU2004312547A1 (en) 2003-12-31 2005-07-21 Taigen Biotechnology Protease inhibitors
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
JP2007532572A (ja) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
US20070196452A1 (en) 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
CN1286529C (zh) 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20060105028A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Systems and methods for treating warts
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
BRPI0615588A2 (pt) * 2005-08-31 2011-05-24 Serentis Ltd uso de um inibidor de aureolisina para o tratamento de condições inflamatórias da pele caracterizadas por colonização com staphylococcus aureus
WO2007032009A2 (en) * 2005-09-15 2007-03-22 Biomas Ltd. Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US20070081962A1 (en) 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
CA2659095C (en) * 2006-07-14 2015-04-28 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
JP2009543866A (ja) 2006-07-18 2009-12-10 ウイラ アイピー プロプライエタリー リミテッド 免疫応答修飾製剤
AU2007279376B2 (en) 2006-07-31 2012-09-06 Wirra Ip Pty Ltd Immune response modifier compositions and methods
CN103382197A (zh) * 2006-09-15 2013-11-06 细胞基因公司 N-甲基氨甲基异吲哚化合物和包含它的组合物及其使用方法
CN104876908A (zh) * 2006-09-26 2015-09-02 细胞基因公司 作为抗肿瘤剂的5-取代的喹唑酮衍生物
ES2607901T3 (es) * 2007-01-31 2017-04-04 Chongxi Yu Profármacos hidrosolubles cargados positivamente de 1H-imidazo[4,5-c]quinolin-4-aminas y compuestos relacionados con ratas de penetración de piel muy altas
US20090018155A1 (en) 2007-02-08 2009-01-15 Gregory Jefferson J Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
WO2008118765A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
CA2679067A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en) 2007-05-08 2008-11-20 The Brigham And Women's Hospital, Inc Methods and products for treating proliferative disorders
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en) 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) * 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009091541A1 (en) 2008-01-15 2009-07-23 Dow Pharmaceutical Sciences, Inc. Imiquimod formulation
PT2176408E (pt) 2008-01-31 2015-04-23 Curevac Gmbh Ácidos nucleicos compreendendo a fórmula (nuglxmgnnv)a e os seus derivados como agentes/adjuvantes imunoestimuladores
US20090246156A1 (en) * 2008-03-31 2009-10-01 Audrey Kunin Anti-acne sunscreen composition
JP2011516478A (ja) * 2008-04-03 2011-05-26 コグネイト ３，エルエルシー 免疫療法のための組成物および方法
JP2011518885A (ja) 2008-04-28 2011-06-30 ノバルティス アーゲー 医薬組成物における使用のためのナノ粒子
EP2303280A2 (en) 2008-05-30 2011-04-06 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CN102196821A (zh) 2008-10-31 2011-09-21 莫贝里德尔马公司 包含至少两种渗透增强剂组合的局部组合物
US20110021555A1 (en) 2008-12-19 2011-01-27 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
AU2010274097B2 (en) 2009-07-13 2016-06-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US9072876B2 (en) * 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
WO2013040447A2 (en) * 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis

Also Published As

Publication number Publication date
AR074802A1 (es) 2011-02-16
US10238644B2 (en) 2019-03-26
TW201040173A (en) 2010-11-16
BRPI0923164A2 (pt) 2016-01-26
IL255163A0 (en) 2017-12-31
IL213628A0 (en) 2011-07-31
DK2378876T3 (en) 2019-03-11
US20200276182A1 (en) 2020-09-03
ES2720149T3 (es) 2019-07-18
US8299109B2 (en) 2012-10-30
EA201100984A1 (ru) 2012-01-30
CR20110338A (es) 2011-11-10
US11318130B2 (en) 2022-05-03
LT2378876T (lt) 2019-04-25
US20110263635A1 (en) 2011-10-27
US20110257217A1 (en) 2011-10-20
MX346455B (es) 2017-03-21
CL2009002183A1 (es) 2011-01-07
US20110257216A1 (en) 2011-10-20
US20110263634A1 (en) 2011-10-27
WO2010080345A1 (en) 2010-07-15
PA8855101A1 (es) 2010-07-27
MX2011001555A (es) 2011-04-14
SI2378876T1 (sl) 2019-05-31
US20110263633A1 (en) 2011-10-27
RS58566B1 (sr) 2019-05-31
IL213628A (en) 2017-11-30
IL255163B (en) 2019-01-31
EP2378876A4 (en) 2012-12-05
TWI442923B (zh) 2014-07-01
CY1121485T1 (el) 2020-05-29
US20110257218A1 (en) 2011-10-20
US9370509B2 (en) 2016-06-21
GEP20146198B (en) 2014-11-25
US20110263636A1 (en) 2011-10-27
HRP20190306T1 (hr) 2019-05-03
EP2378876B1 (en) 2018-11-14
DOP2011000195A (es) 2011-12-15
PE20100469A1 (es) 2010-07-31
PE20142367A1 (es) 2015-01-10
US8236816B2 (en) 2012-08-07
EP2378876A1 (en) 2011-10-26
US8222270B2 (en) 2012-07-17
US20110257219A1 (en) 2011-10-20
US20130210855A1 (en) 2013-08-15
US20110263637A1 (en) 2011-10-27
HUE041944T2 (hu) 2019-06-28
CO6400171A2 (es) 2012-03-15
US20110021555A1 (en) 2011-01-27
PL2378876T3 (pl) 2019-06-28
AU2009335943A1 (en) 2013-10-24
US20160303111A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
HRP20190306T1 (hr) Niže jačine doze formulacija imikvimoda i kratki režimi doziranja kod liječenja aktinične keratoze
IL271132A (en) New preparation and dosage
IL206288A0 (en) Novel dosage and formulation
ZA201205167B (en) Antibody formulation and therapeutic regimens
IL218169A (en) Quinazoline compounds and their pharmaceutical compositions containing them for use in therapy
EP2486061A4 (en) COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTICS
IL208774A0 (en) Compositions comprising weakly basic drugs and controlled-release dosage forms
HK1206360A1 (en) (aza)indolizine derivative and pharmaceutical use thereof ()
EP2461691A4 (en) THERAPEUTIC VITAMIN D SUNSCREEN FORMULATIONS AND METHOD OF USE THEREOF
HK1161984A1 (zh) 劑量方案
ZA201301397B (en) Lower dosage strenght imiquimod formulations and short dosing regimens for treating genital and perianal warts
ZA201004145B (en) Imiquimod formulation
EP2351558A4 (en) THERAPEUTIC AGENT AGAINST TYMPANITES IN REPURITISHES
FR2958166B1 (fr) Compositions pharmaceutiques fortement dosees en biotine
IL218726A (en) Pharmaceuticals for the treatment of Down syndrome
IL223794B (en) Pharmaceutical preparation containing 1-isobutyl-1h-imidazo[4,5c]-quinolin-4-amine or 1(2-methylpropyl)-1h-imidazo[4,5c]-quinolin-4-amine imiquimod for use in the treatment of actinic keratosis
GB2469791B (en) Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
HU0800011D0 (en) Device for animal transport and for temporary restriction of mokement above all for the sake of therapy
HU0900451D0 (en) Cuvette and dosage detector
ZA201106465B (en) A dosage regimen for treating gastric disorders in animals
GB0805206D0 (en) Apparatus and methods for game conversion
GB0823230D0 (en) Apparatus and methods for game conversion